# US 2026/0062410 A1 · Substituted pyrrolopyridine jak inhibitors and methods of making and using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062410 A1
- Document ID: US20260062410A1
- Status: Published application
- Kind: A1
- Application number: 19/086,512
- Filed: 2025-03-21
- Published: 2026-03-05
- Earliest claimed: 2017-11-03
- Assignees: Aclaris Therapeutics, Inc.
- Applicants: Aclaris Therapeutics, Inc.
- Inventors: David Randolph ANDERSON; Susan Landis HOCKERMAN; James Robert BLINN; Eric Jon JACOBSEN
- Web page: https://patentgrep.com/patent/US20260062410A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/00: Drugs for dermatological disorders
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.

## Claims

### Claim at position 1

-42. (canceled)

### Claim 43

A method of treating a JAK1- and/or JAK3-mediated disease in a subject in need thereof comprising administering a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt thereof, of the structure:
wherein JAK1- and/or JAK3-mediated disease is treated.

### Claim 44 (depends on 43)

The method of claim 43, wherein the JAK1- and/or JAK3-mediated disease is selected from atopic dermatitis, psoriasis, hidradenitis suppurativa, prurigo nodularis, vitiligo, alopecia areata, itch, lichen planus, lichen sclerosus, lichen simplex chronicus associated pruritus, lichen planopilaris, seborrheic dermatitis, lupus, systemic lupus erythematosus, systemic sclerosis, scleroderma, dermatomyositis, mixed connective tissue disease, graft vs. host disease, and a combination thereof.

### Claim 45 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is atopic dermatitis.

### Claim 46 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is psoriasis.

### Claim 47 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is hidradenitis suppurativa.

### Claim 48 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is prurigo nodularis.

### Claim 49 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is vitiligo.

### Claim 50 (depends on 49)

The method of claim 49, wherein the vitiligo is selected from segmental vitiligo, unisegmental, vitiligo bisegmental vitiligo, multisegmental vitiligo, non-segmental vitiligo, acral vitiligo, facial vitiligo, acrofacial vitiligo, centrofacial vitiligo, mucosal vitiligo, confetti vitiligo, trichrome vitiligo, marginal inflammatory vitiligo, quadrichrome vitiligo, blue vitiligo, Koebner phenomenon, vulgaris vitiligo, generalized vitiligo, universal vitiligo, mixed vitiligo, nonsegmental associated with segmental vitiligo, focal vitiligo, solitary mucosal vitiligo, vitiligo with or without leukotrichia, and a combination thereof.

### Claim 51 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is alopecia areata.

### Claim 52 (depends on 51)

The method of claim 51, wherein the alopecia areata is patchy alopecia areata, alopecia totalis, alopecia universalis, ophiasis pattern alopecia areata, sisaihpo pattern alopecia areata, androgenetic alopecia (AGA), male and female pattern AGA, scarring alopecia, central centrifugal cicatricial alopecia, frontal fibrosing alopecia, or a combination thereof.

### Claim 53 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is itch.

### Claim 54 (depends on 53)

The method of claim 53, wherein the itch is selected from pruritus, atopic pruritus, xerotic pruritus, pruritus associated with psoriasis, psoriatic itch, psoriasis-associated itch, acute pruritus, chronic pruritus, idiopathic pruritus, chronic idiopathic itch, biliary itch, hepatobiliary-associated itch, renal associated itch/renal itch, uremic itch, cholestasis, intrahepatic cholestasis of pregnancy, lichen simplex chronicus associated pruritus, lymphoma-associated itch, leukemia-associated itch, prurigo nodularis, atopic dermatitis-associated itch, atopic itch/atopic puritis, bullous itch, brachioradial pruritus, neurogenic itch, neuropathic itch, notalgia paresthetica, pruritic popular eruption of HIV, psychogenic itch, swimmer's itch, pruritus or uremic itch, urticarial itch, chronic idiopathic pruritus, idiopathic chronic itch, pruritic urticarial papules and plaques of pregnancy (PUPPP), and a combination thereof.

### Claim 55 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is lichen planus.

### Claim 56 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is lichen sclerosus.

### Claim 57 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is lichen simplex chronicus associated pruritus.

### Claim 58 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is lichen planopilaris.

### Claim 59 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is seborrheic dermatitis.

### Claim 60 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is lupus.

### Claim 61 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is systemic lupus erythematosus.

### Claim 62 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is systemic sclerosis.

### Claim 63 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is scleroderma.

### Claim 64 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is dermatomyositis.

### Claim 65 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is mixed connective tissue disease.

### Claim 66 (depends on 44)

The method of claim 44, wherein the JAK1- and/or JAK3-mediated disease is graft vs. host disease.
